Researchers at UCLA’s Jonsson Comprehensive Cancer Center, including former Damon Runyon Fellow Hong Wu, MD, PhD, discovered that an experimental drug slows growth of ovarian cancer cells and increases survival in animal models. 

In a two-year study, Wu and her colleagues found that the drug NVP-BEZ235 hinders growth by blocking two critical cancer cell signaling pathways.  Remarkably, it also counteracts the resistance developed by many ovarian cancer cells to platinum chemotherapy. 

> Read the whole post: “Experimental Drug Slows Ovarian Cancer Growth”